Suven Life Sciences, a biopharmaceutical company, announced today that the company has secured patents in Australia, China, Europe, South Korea and United States of America. The secured patents are for CNS therapy through mechanism of action - H3 Inverse agonist.
The granted claims of the patent include the class of selective H3 ligands discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Venkat Jasti, CEO of Suven said, 'We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.'
With these new patents, Suven has a total of twenty two granted product patents in Australia, nineteen granted patents from China, seventeen granted patents from Europe, seventeen granted patents from South Korea and twenty three granted patents from USA.
Shares of the company gained Rs 12.10, or 4.34%, to trade at Rs 290.30 at the BSE.